Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction and does not contain financial performance data.
Material Changes
There are no material changes to the company's financial position or operations reported in this filing. The only change noted is a minor acquisition of shares by a connected person.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Mr. S M Bicknell acquired a beneficial interest in 7 Ordinary shares.
- Acquisition Method: The shares were acquired through the re-investment of dividends under a Personal Equity Plan.
- Transaction Date: 6 January 2010.
- Share Price: The acquisition occurred at a price of £13.11 per share.
- Notification Date: The company and the individual were advised of the transaction on 7 January 2010.